RxDoctor Payments Data

Thomas Akers, OD

Optometrist · Rocky Mount, NCNPI 1124090170

Payments from drug & device makers

$3,191in general payments, 2019–2025

Across 87 payments — averaging $36.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$766
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$528
  • Bausch & Lomb Americas Inc.$345
  • Sun Pharmaceutical Industries Inc.$295
  • Coopervision Inc.$220
  • AbbVie$193
  • plus $844 from 14 others

What the payments were for

  • Food & beverage$3,12698%
  • Entertainment$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,191 in reported general payments places this provider in the 80th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,110
Medicare patients
280
Services billed
1,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$11,539
RocklatanNetarsudil Mesylat/Latanoprost15$10,093
CombiganBrimonidine Tartrate/Timolol15$5,062
Brimonidine Tartrate29$4,481
Travoprost36$4,238
Latanoprost306$4,096
SimbrinzaBrinzolamide/Brimonidine Tart13$2,764
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,251
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat93$1,166
Timolol Maleate49$413
Dorzolamide Hcl12$246
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$193$16,60130 claims
Aerie Pharmaceuticals, Inc.Rocklatan$101$10,09315 claims
AlconSimbrinza$766$2,76413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →